Diagnostics Pipeline: Testing for Intestinal Parasites Takes Step Forward
The EasyScreen assay received 510(k) clearance from the Food and Drug Administration earlier this year–but with a catch
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
The EasyScreen assay received 510(k) clearance from the Food and Drug Administration earlier this year–but with a catch
September was an eventful month for one of the hottest products on the consumer genetic test market, the Cologuard multi-target stool DNA test (mtSDNA) for colorectal cancer screening produced by Exact Sciences. The month started badly with the release of a CMS-sponsored research report finding Cologuard “less effective and considerably more costly” than alternatives. Although Exact Sciences quickly criticized the report and its analytical methodology, its stock took a beating.
By Sean McSweeney bio
Today, laboratory billing claims require more and more data to successfully get paid.
One of the biggest reasons your claims may be getting denied is because…
From - Diagnostic Testing & Emerging Technologies
The US Preventive Services Task Force (USPSTF) issued updated recommendations for BRCA-related cancer risk assessment…